Epidemiology, virulence factors and management of the pneumococcus.

F1000Research

Volumn 5, Issue , 2016, Pages

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BIOFILM; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSENESCENCE; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PNEUMONIA SEVERITY INDEX; PREVALENCE; REVIEW; SMOKING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 85010972067     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.9283.1     Document Type: Review

References (110)

1. File TM Jr, Marrie TJ: Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010; 122(2): 130-41.
2. Isturiz RE, Luna CM, Ramirez J: Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010; 14(10): e852-6.
3. Shibl AM, Memish ZA, Ibrahim E, et al.: Burden of adult community-acquired pneumonia in the Middle East/North Africa region. Rev Med Microbiol. 2010; 21(1): 11-20.
4. Song JH, Thamlikitkul V, Hsueh PR: Clinical and economic burden of communityacquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011; 38(2): 108-17.
5. Welte T, Torres A, Nathwani D: Clinical and economic burden of communityacquired pneumonia among adults in Europe. Thorax. 2012; 67(1): 71-9.
6. Feldman C, Anderson R: Recent advances in our understanding of Streptococcus pneumoniae infection. F1000Prime Rep. 2014; 6: 82.
7. Drijkoningen JJ, Rohde GG: Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014; 20(Suppl 5): 45-51.
8. Said MA, Johnson HL, Nonyane BA, et al.: Estimating the burden of pneumococcal pneumonia among adults: a systematic review and metaanalysis of diagnostic techniques. PLoS One. 2013; 8(4): e60273.
9. Torres A, Blasi F, Peetermans WE, et al.: The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014; 33(7): 1065-79.
10. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, et al.: The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013; 32(3): 305-16.
11. Pletz MW, von Baum H, van der Linden M, et al.: The burden of pneumococcal pneumonia-experience of the German competence network CAPNETZ. Pneumologie. 2012; 66(8): 470-5.
12. Musher DM, Roig IL, Cazares G, et al.: Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013; 67(1): 11-8.
13. Jain S, Self WH, Wunderink RG, et al.: Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5): 415-27.
14. Blasi F, Mantero M, Santus P, et al.: Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012; 18(Suppl 5): 7-14.
15. Ash SY, Sheffield JV: Pneumococcus. Med Clin North Am. 2013; 97(4): 647-66, x-xi.
16. Cilloniz C, Ardanuy C, Vila J, et al.: What is the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016; 22(3): 227-34.
17. Low DE: What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?). Infect Dis Clin North Am. 2013; 27(1): 87-97.
18. Cilloniz C, Albert RK, Liapikou A, et al.: The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia. Am J Respir Crit Care Med. 2015; 191(11): 1265-72.
19. Niederman MS: Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy? Am J Respir Crit Care Med. 2015; 191(11): 1216-7.
20. Kim L, McGee L, Tomczyk S, et al.: Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre-and Post-Conjugate Vaccine Eras: a United States Perspective. Clin Microbiol Rev. 2016; 29(3): 525-52.
21. Imöhl M, Reinert RR, van der Linden M: Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int J Med Microbiol. 2015; 305(7): 776-83.
22. Tomczyk S, Lynfield R, Schaffner W, et al.: Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016; 62(9): 1119-25.
23. Myint TT, Madhava H, Balmer P, et al.: The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013; 30(2): 127-51.
24. Griffin MR, Zhu Y, Moore MR, et al.: U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013; 369(2): 155-63.
25. Simonsen L, Taylor RJ, Schuck-Paim C, et al.: Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014; 2(5): 387-94.
26. Chavanet P: Pneumococcus infections: is the burden still as heavy? Med Mal Infect. 2012; 42(4): 149-53.
27. Weinberger DM, Malley R, Lipsitch M: Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807): 1962-73.
28. Cillóniz C, Amaro R, Torres A: Pneumococcal vaccination. Curr Opin Infect Dis. 2016; 29(2): 187-96.
29. van der Linden M, Perniciaro S, Imöhl M: Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015; 15: 207.
30. Waight PA, Andrews NJ, Ladhani SN, et al.: Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015; 15(5): 535-43.
31. Chalmers JD, Campling J, Dicker A, et al.: A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016; 16(1): 77.
32. Sanz Herrero F, Blanquer Olivas J: Microbiology and risk factors for communityacquired pneumonia. Semin Respir Crit Care Med. 2012; 33(3): 220-31.
33. Feldman C, Anderson R: The role of Streptococcus pneumoniae in CAP. Semin Respir Crit Care Med. In press.
34. Krone CL, van de Groep K, Trzcinski K, et al.: Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir Med. 2014; 2(2): 141-53.
35. Nuorti JP, Butler JC, Farley MM, et al.: Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000; 342(10): 681-9.
36. Bello S, Menéndez R, Torres A, et al.: Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014; 146(4): 1029-37.
37. Feldman C, Anderson R: Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus. Semin Respir Crit Care Med. 2016; 37(2): 214-29.
38. Boikos C, Quach C: Risk of invasive pneumococcal disease in children and adults with asthma: a systematic review. Vaccine. 2013; 31(42): 4820-6.
39. Torres A, Peetermans WE, Viegi G, et al.: Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013; 68(11): 1057-65.
40. Torres A, Blasi F, Dartois N, et al.: Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70(10): 984-9.
41. Steel HC, Cockeran R, Anderson R, et al.: Overview of communityacquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013; 2013: 490346.
42. Feldman C, Anderson R: Review: current and new generation pneumococcal vaccines. J Infect. 2014; 69(4): 309-25.
43. Geno KA, Gilbert GL, Song JY, et al.: Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3): 871-99.
44. Musher DM: Pneumococcal vaccination in adults. UpToDate. accessed July 7, 2016.
45. Jardine A, Menzies RI, McIntyre PB: Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010; 29(7): 607-12.
46. Afonso ET, Minamisava R, Bierrenbach AL, et al.: Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerging Infect Dis. 2013; 19(4): 589-97.
47. Sgambatti S, Minamisava R, Bierrenbach AL, et al.: Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine. 2016; 34(5): 663-70.
48. Fernández V JP, Goecke HC, von Borries C, et al.: [Incidence of admissions due to pneumonia in children under 24 months old before and after the introduction of the 10-valent pneumococcal conjugate vaccine into the National Immunization Program of Chile]. Rev Chil Pediatr. 2015; 86(3): 168-72.
49. Harboe ZB, Dalby T, Weinberger DM, et al.: Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8): 1066-73.
50. Lepoutre A, Varon E, Georges S, et al.: Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015; 33(2): 359-66.
51. Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML: Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines. 2014; 2(6): 155-8.
52. Vogel AM, Trenholme AA, Stewart JM, et al.: Impact of pneumococcal vaccine on hospital admission with lower respiratory infection in children resident in South Auckland, New Zealand. N Z Med J. 2013; 126(1378): 26-35.
53. Becker-Dreps S, Amaya E, Liu L, et al.: Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014; 33(6): 637-42.
54. Madhi SA, Bamford L, Ngcobo N: Effectiveness of pneumococcal conjugate vaccine and rotavirus vaccine introduction into the South African public immunisation programme. S Afr Med J. 2014; 104(3 Suppl 1): 228-34.
55. Grijalva CG, Nuorti JP, Arbogast PG, et al.: Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007; 369(9568): 1179-86.
56. Simonsen L, Taylor RJ, Young-Xu Y, et al.: Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011; 2(1): e00309-10.
57. Moore MR, Link-Gelles R, Schaffner W, et al.: Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, populationbased surveillance. Lancet Infect Dis. 2015; 15(3): 301-9.
58. Keller LE, Robinson DA, McDaniel LS: Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. MBio. 2016; 7(2): e01792.
59. Nelson AL, Roche AM, Gould JM, et al.: Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun. 2007; 75(1): 83-90.
60. Park IH, Kim K, Andrade AL, et al.: Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio. 2012; 3(3): pii: e00035-12.
61. Hammerschmidt S, Wolff S, Hocke A, et al.: Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun. 2005; 73(8): 4653-67.
62. Keller LE, Jones CV, Thornton JA, et al.: PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun. 2013; 81(1): 173-81.
63. Keller LE, Bradshaw JL, Pipkins H, et al.: Surface Proteins and Pneumolysin of Encapsulated and Nonencapsulated Streptococcus pneumoniae Mediate Virulence in a Chinchilla Model of Otitis Media. Front Cell Infect Microbiol. 2016; 6: 55.
64. Moscoso M, García E, López R: Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J Bacteriol. 2006; 188(22): 7785-95.
65. Schaffner TO, Hinds J, Gould KA, et al.: A point mutation in cpsE renders Streptococcus pneumoniae nonencapsulated and enhances its growth, adherence and competence. BMC Microbiol. 2014; 14: 210.
66. Musher DM, Rueda AM, Kaka AS, et al.: The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007; 45(2): 158-65.
67. Brown AO, Mann B, Gao G, et al.: Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014; 10(9): e1004383.
68. Orihuela CJ, Mahdavi J, Thornton J, et al.: Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest. 2009; 119(6): 1638-46.
69. Mook-Kanamori BB, Geldhoff M, van der Poll T, et al.: Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011; 24(3): 557-91.
70. Alhamdi Y, Neill DR, Abrams ST, et al.: Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015; 11(5): e1004836.
71. Alhamdi Y, Zi M, Abrams ST, et al.: Circulating Histone Concentrations Differentially Affect the Predominance of Left or Right Ventricular Dysfunction in Critical Illness. Crit Care Med. 2016; 44(5): e278-88.
72. Ohkuni H, Nagamune H, Ozaki N, et al.: Characterization of recombinant Streptococcus mitis-derived human platelet aggregation factor. APMIS. 2012; 120(1): 56-71.
73. Nel JG, Durandt C, Mitchell TJ, et al.: Pneumolysin Mediates Platelet Activation In Vitro. Lung. 2016; 194(4): 589-93.
74. Gilley RP, González-Juarbe N, Shenoy AT, et al.: Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun. 2016; 84(5): 1457-69.
75. Rai P, Parrish M, Tay IJ, et al.: Streptococcus pneumoniae secretes hydrogen peroxide leading to DNA damage and apoptosis in lung cells. Proc Natl Acad Sci U S A. 2015; 112(26): E3421-30.
76. Canli Ö, Alankus YB, Grootjans S, et al.: Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors. Blood. 2016; 127(1): 139-48.
77. Saleh M, Bartual SG, Abdullah MR, et al.: Molecular architecture of Streptococcus pneumoniae surface thioredoxin-fold lipoproteins crucial for extracellular oxidative stress resistance and maintenance of virulence. EMBO Mol Med. 2013; 5(12): 1852-70.
78. Hsieh YC, Lin TL, Lin CM, et al.: Identification of PblB mediating galactosespecific adhesion in a successful Streptococcus pneumoniae clone. Sci Rep. 2015; 5: 12265.
79. Escolano-Martínez MS, Domenech A, Yuste J, et al.: DiiA is a novel dimorphic cell wall protein of Streptococcus pneumoniae involved in invasive disease. J Infect. 2016; 73(1): 71-81.
80. Robb M, Robb CS, Higgins MA, et al.: A Second β-Hexosaminidase Encoded in the Streptococcus pneumoniae Genome Provides an Expanded Biochemical Ability to Degrade Host Glycans. J Biol Chem. 2015; 290(52): 30888-900.
81. Terra VS, Zhi X, Kahya HF, et al.: Pneumococcal 6-Phospho-β-Glucosidase (BglA3) Is Involved in Virulence and Nutrient Metabolism. Infect Immun. 2015; 84(1): 286-92.
82. Romero-Espejel ME, Rodríguez MA, Chávez-Munguía B, et al.: Characterization of Spbhp-37, a Hemoglobin-Binding Protein of Streptococcus pneumoniae. Front Cell Infect Microbiol. 2016; 6: 47.
83. Mohan S, Hertweck C, Dudda A, et al.: Tuf of Streptococcus pneumoniae is a surface displayed human complement regulator binding protein. Mol Immunol. 2014; 62(1): 249-64.
84. Rai AN, Thornton JA, Stokes J, et al.: Polyamine transporter in Streptococcus pneumoniae is essential for evading early innate immune responses in pneumococcal pneumonia. Sci Rep. 2016; 6: 26964.
85. Chang CY, Li BR, Li YK: An l-ascorbate-6-phosphate lactonase from Streptococcus pneumoniae ATCC 49136 strain reveals metallo-β-lactamase activity. Int J Antimicrob Agents. 2016; 47(5): 416-8.
86. Garin N, Genné D, Carballo S, et al.: β-Lactam monotherapy vs β-lactammacrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014; 174(12): 1894-901.
87. Lee JS, Giesler DL, Gellad WF, et al.: Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA. 2016; 315(6): 593-602.
88. Gattarello S: What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy. Curr Infect Dis Rep. 2015; 17(10): 501.
89. Gattarello S, Borgatta B, Solé-Violán J, et al.: Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest. 2014; 146(1): 22-31.
90. Gattarello S, Lagunes L, Vidaur L, et al.: Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care. 2015; 19: 335.
91. Sligl WI, Asadi L, Eurich DT, et al.: Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and metaanalysis. Crit Care Med. 2014; 42(2): 420-32.
92. McFarlane A, Sligl W: The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia. Curr Infect Dis Rep. 2015; 17(12): 50.
93. Emmet O'Brien M, Restrepo MI, Martin-Loeches I: Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir Investig. 2015; 53(5): 201-9.
94. Trac MH, McArthur E, Jandoc R, et al.: Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ. 2016; 188(7): E120-9.
95. Wunderink RG, Mandell L: Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med. 2012; 33(3): 311-8.
96. Faverio P, Restrepo MI: Non-antibiotic therapies for CAP. In Eur Respir Monogr. Edited by Chalmers J, Pletz MA, Aliberti S. United Kingdom: European Respiratory Society; 2014; 63: 219-233.
97. Salih W, Short PM, Schembri S: Macrolides as anti-inflammatory agents in CAP. In Eur Respir Monogr. Edited by Chalmers J, Pletz MA, Aliberti S. United Kingdom: European Respiratory Society; 2014; 63: 243-255.
98. Blum CA, Nigro N, Briel M, et al.: Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977): 1511-8.
99. Siemieniuk RA, Meade MO, Alonso-Coello P, et al.: Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163(7): 519-28.
100. Feldman C, Anderson R: Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis. 2016; 8(3): E162-71.
101. Feldman C, Anderson R: Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care. 2016; 22(5): 477-84.
102. Ludwig E, Bonanni P, Rohde G, et al.: The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012; 21(123): 57-65.
103. Mongardon N, Max A, Bouglé A, et al.: Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012; 16(4): R155.
104. Naucler P, Darenberg J, Morfeldt E, et al.: Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax. 2013; 68(6): 571-9.
105. Burgos J, Luján M, Larrosa MN, et al.: Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J. 2014; 43(2): 545-53.
106. Gili-Miner M, López-Méndez J, Béjar-Prado L, et al.: Alcohol Use Disorders and Community-Acquired Pneumococcal Pneumonia: Associated Mortality, Prolonged Hospital Stay and Increased Hospital Spending. Arch Bronconeumol. 2015; 51(11): 564-70.
107. Ruiz LA, Zalacain R, Capelastegui A, et al.: Bacteremic pneumococcal pneumonia in elderly and very elderly patients: host-and pathogen-related factors, process of care, and outcome. J Gerontol A Biol Sci Med Sci. 2014; 69(8): 1018-24.
108. Burgos J, Luján M, Larrosa MN, et al.: The problem of early mortality in pneumococcal pneumonia: a study of risk factors. Eur Respir J. 2015; 46(2): 561-4.
109. Beatty JA, Majumdar SR, Tyrrell GJ, et al.: Current Smoking and Reduced Mortality in Bacteremic Pneumococcal Pneumonia: A Population-Based Cohort Study. Chest. 2016; pii: S0012-3692(16)48803-3.
110. Grau I, Ardanuy C, Cubero M, et al.: Declining mortality from adult pneumococcal infections linked to children's vaccination. J Infect. 2016; 72(4): 439-49.